Achillion Pharma (Nasdaq: ACHN) $11.96. Achillion Pharma making some serious gains Tuesday as M&A speculation runs rampant in the sector. Chatter heated up following Roche’s move to acquire Intermune, which was announced last Sunday.
Avanir Pharma (Nasdaq: AVNR) $. Avanir Pharma announced the enrollment of the first patient into a phase II study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). AVP-786 is a novel investigational drug consisting of a combination of deuterium modified dextromethorphan and ultra-low dose quinidine.
